Jaroszewicz, Jerzy

Publishing since 2002 (Junior)

Has published 21 publications in 9 years

Number of publications published per year by Jaroszewicz, Jerzy. (Source : PubMed)

Distribution of publications types for Jaroszewicz, Jerzy. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)

Recent publications

•  Jaroszewicz J, Serrano BC, Wursthorn K, Deterding K, Schlue J, Raupach R, Flisiak R, Bock CT, Manns MP, Wedemeyer H, Cornberg M. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective.  J. Hepatol.  2010;52;4  
•  Stegmann KA, Björkström NK, Liermann H, Ciesek S, Riese P, Wiegand J, Hadem J, Suneetha PV, Jaroszewicz J, Wang C, Schlaphoff V, Fytili P, Cornberg M, Manns MP, Geffers R, Pietschmann T, Guzmán CA, Ljunggren HG, Wedemeyer H. Interferon-Alfa-Induced Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand on Natural Killer Cells Is Associated With Control of Hepatitis C Virus Infection.  Gastroenterology  2010  
•  Jaroszewicz J, Rogalska M, Kalinowska A, Wierzbicka I, Parfieniuk A, Flisiak R. [Prevalence of antibodies against hepatitis E virus among students from India living in Bialystok, Poland]  Przegl Epidemiol  2008;62;2  
•  Flisiak R, Jaroszewicz J. [Treatment recommendations of chronic hepatitis B. Did the world escape us?]  Przegl Epidemiol  2008;62;1  
•  Parfieniuk A, Jaroszewicz J, Flisiak R. Specifically targeted antiviral therapy for hepatitis C virus.  World J. Gastroenterol.  2007;13;43  
•  Wiercinska-Drapalo A, Jaroszewicz J, Tarasow E, Siergiejczyk L, Prokopowicz D. The possible association between serum cholesterol concentration and decreased bone mineral density as well as intravertebral marrow fat in HIV-1 infected patients.  Infection  2007;35;1  
•  Jaroszewicz J, Pełszyńska MJ, Kalinowska A, Wierzbicka I, Flisiak R, Prokopowicz D. [Analysis of prognostic factors in patients with autoimmune hepatitis]  Pol. Arch. Med. Wewn.  2006;115;4  
•  Lapinski TW, Jaroszewicz J, Wiercinska-Drapalo A. Concentrations of soluble Fas and soluble Fas ligand as indicators of programmed cell death among patients coinfected with Human Immunodeficiency Virus and Hepatitis C Virus.  Viral Immunol.  2006;19;3  
•  Jaroszewicz J, Wiercinska-Drapalo A, Lapinski TW, Prokopowicz D, Rogalska M, Parfieniuk A. Does HAART improve renal function? An association between serum cystatin C concentration, HIV viral load and HAART duration.  Antivir. Ther. (Lond.)  2006;11;5  
•  Flisiak R, Jaroszewicz J, Lapinski TW, Flisiak I, Prokopowiczi D. Effect of pegylated interferon alpha 2b plus ribavirin treatment on plasma transforming growth factor-beta1, metalloproteinase-1, and tissue metalloproteinase inhibitor-1 in patients with chronic hepatitis C.  World J. Gastroenterol.  2005;11;43  

[ See timeline ] [ See all publications ]